Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 21.6% – What’s Next?

by · The Cerbat Gem

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s stock price was up 21.6% during trading on Wednesday . The company traded as high as $4.93 and last traded at $4.83. Approximately 21,567,297 shares traded hands during trading, a decline of 7% from the average daily volume of 23,082,207 shares. The stock had previously closed at $3.97.

Analysts Set New Price Targets

A number of equities analysts have issued reports on RXRX shares. Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $8.20.

Check Out Our Latest Analysis on RXRX

Recursion Pharmaceuticals Stock Up 27.7 %

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $6.83 and its 200-day moving average price is $6.84. The stock has a market capitalization of $2.32 billion, a PE ratio of -3.76 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period last year, the firm posted ($0.42) earnings per share. The company’s revenue was down 57.8% compared to the same quarter last year. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Decker Retirement Planning Inc. purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $26,000. Private Trust Co. NA purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $27,000. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Finally, NewEdge Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock valued at $53,000 after purchasing an additional 2,387 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

See Also